Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €12.58 EUR
Change Today +0.105 / 0.84%
Volume 16.0
TCE1 On Other Exchanges
Symbol
Exchange
Frankfurt
As of 3:06 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

celldex therapeutics inc (TCE1) Snapshot

Open
€12.29
Previous Close
€12.48
Day High
€12.58
Day Low
€11.84
52 Week High
03/19/15 - €30.72
52 Week Low
10/2/14 - €9.60
Market Cap
1.2B
Average Volume 10 Days
616.2
EPS TTM
--
Shares Outstanding
98.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELLDEX THERAPEUTICS INC (TCE1)

celldex therapeutics inc (TCE1) Related Bloomberg News

View More Bloomberg News

celldex therapeutics inc (TCE1) Related Businessweek News

No Related Businessweek News Found

celldex therapeutics inc (TCE1) Details

Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, as well as in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, as well as in Phase II study for the treatment of metastatic melanoma. It also has various earlier stage drug candidates in clinical development, including varlilumab (CDX-1127), a fully human therapeutic monoclonal antibody for cancer indications; CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells for cancer indications; and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. The company’s preclinical product candidate includes CDX-014, a fully-human monoclonal antibody-drug conjugate that targets T-cell TIM-1, a molecule, which is upregulated in various cancers comprising renal cell and ovarian carcinomas. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Alteris Therapeutics, Inc.; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc., as well as clinical trial collaboration with Roche Holding, Bristol-Myers Squibb Company, and Oncothyreon Inc. The company is headquartered in Hampton, New Jersey.

156 Employees
Last Reported Date: 02/24/15

celldex therapeutics inc (TCE1) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $814.1K
Founder, Chief Scientific Officer and Executi...
Total Annual Compensation: $543.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $419.1K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $556.4K
Chief Business Officer and Senior Vice Presid...
Total Annual Compensation: $419.6K
Compensation as of Fiscal Year 2014.

celldex therapeutics inc (TCE1) Key Developments

Celldex Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Celldex Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $2.2 million against $0.6 million a year ago. Operating loss was $32.8 million against $28.5 million a year ago. Net loss was $32.4 million or $0.33 per basic and diluted share against $28.3 million or $0.32 per basic and diluted share a year ago. The increase in total revenue in the second quarter of 2015 and the six months ended June 30, 2015 was primarily due to clinical trial collaboration with Bristol-Myers Squibb and research and development agreement with Rockefeller University.   For the six months, the company reported total revenue of $2.7 million against $1.0 million a year ago. Operating loss was $63.7 million against $60.0 million a year ago. Net loss was $62.5 million or $0.65 per basic and diluted share against $58.2 million or $0.65 per basic and diluted share a year ago.

Celldex Therapeutics, Inc. to Report Q2, 2015 Results on Aug 10, 2015

Celldex Therapeutics, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 10, 2015

Celldex Therapeutics, Inc., Q2 2015 Earnings Call, Aug 10, 2015

Celldex Therapeutics, Inc., Q2 2015 Earnings Call, Aug 10, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TCE1:GR €12.58 EUR +0.105

TCE1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TCE1.
View Industry Companies
 

Industry Analysis

TCE1

Industry Average

Valuation TCE1 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLDEX THERAPEUTICS INC, please visit www.celldextherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.